---
document_datetime: 2023-09-21 19:14:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/nespo-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: nespo-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.537071
conversion_datetime: 2025-12-23 07:30:41.324863
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## PROCEDURAL STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 September 2003 please refer to module 8B.

- -On 13 July 2001, the EMEA issued a notification for the following type I variation: extension of the shelf-life of the active substance.
- -On 13 July 2001, the EMEA issued a notification for the following type I variation: extension of the shelf-life of the finished product.

| Scope                                                                                                                                         | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Additional indication                                                                                                                         | II/4                 | II                       | 28.05.02                            | 22.08.02                                 |
| Change in the name of a manufacturer of the medicinal product                                                                                 | I/5                  | I                        | 11.04.02                            | 16.05.02                                 |
| Change in test procedure of active substance                                                                                                  | I/6                  | I                        | 11.04.02                            | 16.05.02                                 |
| Change in test procedure for starting material/intermediate used in manufacturing of active substance                                         | I/7                  | longer I                 | 11.04.02                            | 16.05.02                                 |
| Change in test procedure of active substance                                                                                                  | I/8                  | I                        | 29.05.02                            | 31.05.02                                 |
| Change in manufacture of active substance                                                                                                     | I/9                  | I                        | 27.06.02                            | 30.07.02                                 |
| Minor change of manufacturing process                                                                                                         | I/10                 | I                        | 27.06.02                            | 10.07.02                                 |
| Batch size of active substance                                                                                                                | I/11                 | I                        | 27.06.02                            | 10.07.02                                 |
| Change in test procedure of medicinal product                                                                                                 | I/12                 | I                        | 21.06.02                            | 10.07.02                                 |
| Change in the address of theMAH                                                                                                               | I/13                 | I                        | 30.08.02                            | 11.10.02                                 |
| Update of Summary of Product Characteristics and Package Leaflet                                                                              | II/15                | II                       | 21.11.02                            | 27.02.03                                 |
| Extension of Indication                                                                                                                       | II/16                | II                       | 22.05.03                            | 11.08.03                                 |
| Change in the batch size of finished product                                                                                                  | I/17                 | I                        | 19.03.03                            | 02.04.03                                 |
| no Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                | I/18                 | I                        | 10.04.03                            | 24.04.03                                 |
| Change in specification of starting material/intermediate used in manuf. of the active substance                                              | I/19                 | I                        | 03.04.03                            | 08.04.03                                 |
| Update of or change(s) to the pharmaceutical documentation and Change(s) to the test method(s) and/or specifications for the finished product | II/20                | II                       | 24.07.03                            | 28.07.03                                 |

Medicinal product no longer authorised -On 31 July 2001, the EMEA issued an opinion on a transfer of the marketing authorisation to Domp√©  Biotec  S.p.A.  The  Commission  Decision  amending  the  Community  Marketing Authorisation was adopted on 1 October 2001. Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.